Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747.

Autor: Scott E; Department of Medicine.

Publikováno v: Urologic oncology [Urol Oncol] 2017 Mar; Vol. 35 (3), pp. 123. Date of Electronic Publication: 2017 Feb 01.

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747

Autor: Eggener Scott

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 35:123

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7354a148c3a5e8b081e54b035c188ef7
https://doi.org/10.1016/j.urolonc.2016.12.021

Development and characterization of high-throughput serological assays to measure magnitude and functional immune response against S. Paratyphi A in human samples.

Autor: Carducci M; GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy., Massai L; GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy., Lari E; VisMederi S.r.l., Siena, Italy., Semplici B; VisMederi S.r.l., Siena, Italy., Grappi S; VisMederi S.r.l., Siena, Italy., Maria N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Jones E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Conti V; GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy., Piu P; VisMederi S.r.l., Siena, Italy., Scorza FB; GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy., Iturriza-Gómara M; GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy., Montomoli E; VisMederi S.r.l., Siena, Italy.; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy., Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Rondini S; GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy., Rossi O; GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Oct 30; Vol. 15, pp. 1443137. Date of Electronic Publication: 2024 Oct 30 (Print Publication: 2024).

Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81.

Autor: Shariat SF; Division of Urology, Sidney Kimmel Center for Prostate and Urologic Cancer, 1275 York Avenue, Box 27, New York, NY 10065, USA. sfshariat@gmail.com, Karam JA, Karakiewicz PI

Publikováno v: European urology [Eur Urol] 2009 Jan; Vol. 55 (1), pp. 250-2.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421

Autor: Lara Jr., P.N., Plets, M., Tangen, C., Gertz, E., Vogelzang, N.J., Hussain, M., Twardowski, P.W., Garzotto, M.G., Monk, J.P., Carducci, M., Goldkorn, A., Mack, P.C., Thompson, I., Van Loan, M., Quinn, D.I.

Publikováno v: In Cancer Treatment and Research Communications 2018 16:18-23